Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UMC119-06-05 in mild to moderate knee osteoarthritis
NCT04893174Phase 1Unknown
- Sponsor
- Meridigen Biotech Co., Ltd.
- Start
- Sep 2022
- Primary completion
- Sep 2024
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of UMC119-06-05 in knee osteoarthritis (OA), sponsored by Meridigen Biotech Co., Ltd. Primary endpoint: Incidence and frequency of adverse events at 1 month. Status: unknown.
02
Drugs
UMC119-06-05
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT04893174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04893174.